Transforming Science into Cures
To Build a Fully Integrated Global Gene and Cell Therapy Company with Industry-Leading R&D, Manufacturing and Commercialization Capabilities
Building an Innovative Gene Therapy Pipeline in Eye, CNS, and Liver-Directed Diseases
Efficient, Excellent, Ownership, People-First
Reimaging Gene Therapy
AAVarta® AAV capsid in silico evolution discovery platform
Constellation® AI aided DNA expression cassette design platform
Progress® Data-driven protein engineering platform
Commercial-scale manufacturing capabilities
Developing the most advanced one-time curative, safe and effective gene and cell therapies for patients around the world.
Exegenesis Bio is a clinical-stage global cell and gene therapy company that operates in Philadelphia, Boston, China, and Singapore. Founded in 2019 with strong financial backing, the company has built a broad pipeline of innovative genetic medicines and fully integrated manufacturing capabilities. The company is advancing an early to clinical-stage gene therapy pipeline with three initial focused therapeutic areas: CNS, ophthalmology, and Liver. The company’s vision is to develop and increase access to gene and cell therapies for patients around the world.